DOI: 10.1055/s-00000005

Aktuelle Rheumatologie

References

Aggarwal R, Charles-Schoeman C, Schessl J. et al
Prospective, double-blind, randomized, placebo-controlled phase III study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis („ProDERM Study“).

Medicine (Baltimore) 2021;
100: e23677

Download Bibliographical Data

Access:
Access: